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DNA intercalating and minor groove binding compounds are new weapons in the battle against malignant 
diseases. These antineoplastic agents target the DNA molecule and interfere with the cell cycle leading to 
rapidly proliferating cell death. They are mainly derivates of a naturally occurring organic compound 
derived from a microorganism or plant. Intercalators usually act as topoisomerase I and/or II poisons, while 
the mechanisms of DNA minor groove binders are a combination of several steps including topoisomerase 
poisoning. This paper gives an overview of some of the developed DNA intercalating and minor groove 
binding compounds, as well as an explanation of their chemical structures, origins, and application in 
chemotherapy. 
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Cancer or neoplasm is one of the major diseases 
of modern society, appearing in all age groups. The 
notion that cancer is a multi-step process involving 
accrued genetic damage has now been generally well-
accepted (1).Cancer is characterised by rapid, 
abnormal, and uncontrolled speciﬁ c cell division with 
increased rate of DNA synthesis and very fast 
metabolism that requires a high rate of glycolysis 
(2). 
When it comes to the treatment of cancer, nature 
was the main source of remedies until the middle of 
the nineteenth century when aspirin, the ﬁ rst synthetic 
remedy, was made (3). In the last 70 years, more than 
175 antitumour drugs have been produced and 
commercialised, 65 % of which were derived from 
natural products (4, 5) or were newly-synthesized 
molecules that contained pharmacophores from 
natural products (3). Chemicals that alkylate DNA 
have been used in cancer treatment since 1942 (1). To 
this day, antineoplastic therapy has been primarily 
quantitative rather than qualitative because the impact 
of a therapy is measured through its killing effects and 
not its speciﬁ city. Such therapies are most effective 
in rapidly dividing tumour cells like lymphomas and 
leukaemias but also affect normal rapidly dividing 
cells such as bone marrow cells (6) and various 
epithelial tissues (7). An ideal anticancer drug should 
speciﬁ cally target malignant cancer cells and leave 
non-malignant cells unaffected (6). Having in mind 
that the molecular structure of a single tumour type 
differs between individuals, chemotherapy cannot be 
considered reliable. Modern antitumour therapeutic 
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approaches include case individualisation whenever 
possible as well as the application of modern 
techniques such as DNA microarrays in order to 
achieve this individualisation (8). 
Molecular studies are showing promise in the 
development of more efﬁ cient antitumour strategies 
(9). Since the unravelling of the mechanisms behind 
tumour development, it became clear that DNA is the 
main driving force in tumourogenesis (10) and the 
main intracellular target in cancer chemotherapy (11). 
DNA is a fountain of genetic information with a well-
known and studied structure, which makes it a frequent 
target in drug design. Alterations to gene expression 
by means of small DNA binding molecules were 
proposed some time ago and are constantly being 
improved. Targeting DNA/RNA with small molecules 
can give rise to versatile therapeutic results (12, 13). 
The complex created between DNA and a small 
molecule can modify normal gene expression leading 
to alterations in the regulation of cell growth (14). The 
mode of action for most DNA-affecting antineoplastic 
agents is either the inhibition of DNA synthesis or 
irreversible and/or reversible DNA damage. DNA-
small molecule interactions are driven by two main 
modes of binding: covalent and non-covalent. The two 
main models for the most non-covalent DNA-small 
molecule interaction are intercalation and groove 
binding (14). This review focuses on compounds 
belonging to these two groups. DNA minor groove 
binders (MGBs), one of the most widely studied type 
of small molecules (4), can be grouped into two 
functional groups: 1) substances that cause permanent 
DNA damage and 2) substances that react with DNA 
solely physically and induce reimbursement inhibition 
of DNA-dependent function (15). DNA intercalation 
provokes structural changes in DNA leading to 
intrusion in the recognition and function of DNA-
associated proteins such as polymerases, transcription 
factors, DNA repair systems, and, especially, 
topoisomerases (16). 
There are numerous articles on chemotherapeutic 
drugs used in clinical practice. The main goal of this 
review is to offer a short retrospective of DNA binding/
intercalating drugs applied in chemotherapy (Figure 
1) according to their mechanism of action and origin. 
The drugs described in this article are the basis for 
future generations of anticancer therapeutics focusing 
on “targeted” small molecule- and protein/antibody-
based drugs that will introduce receptor-targeted 
therapies, downstream effectors, and antiangiogenic 
compounds (17). Many are already in clinical use and 
some are promising therapeutics currently under 
research. 
DNA intercalators
DNA intercalators are a group of compounds with 
diverse structure and the ability to bind ﬁ rmly but 
reversibly to DNA by intercalation of a ﬂ at, aromatic 
chromophore between the base pairs (18). The only 
recognised forces that maintain the stability of the 
complex, even more than DNA alone, are van der 
Waals, hydrogen bonding, hydrophobic effects, and/or 
charge transfer forces (19). Classical intercalators have 
a straight, heteroaromatic ring which comes in 
between two neighbouring base pairs. Interaction leads 
to structural changes of the DNA molecule resulting 
in the partial unwinding of the DNA molecule and 
extension of DNA chain by one base pair. Most 
clinically-used DNA-intercalating compounds are 
powerful inhibitors of DNA and RNA synthesis and 
this has been regarded as their primary mode of 
action. 
Their second major biological effect is the 
provocation of DNA damage, e.g. sister chromatid 
exchange (20) and micronuclei (21), which is closely 
correlated with cytotoxicity levels (18). Moreover, 
DNA damage can originate from the interference of 
DNA-intercalating agents with topoisomerase II (topo 
II), an enzymatic protein entrusted with the role of 
maintaining the correct topological properties of DNA 
in cells (18). In general, topoisomerase are nuclear 
enzymes necessary for the maintenance of DNA 
structure. They are direct participants in the recognition 
of DNA and the fundamental steps of cellular growth 
when DNA replication is active, as well as in the S 
phase of the cell cycle in which topology of DNA 
plays a signiﬁ cant role. Topoisomerases inﬂ uence 
chromatin arrangement in the M phase of the cell cycle 
indicating that they can be poisoned not only in the S 
but also in the M phase (19). Topoisomerases can be 
grouped into two main classes: topoisomerase I (topo 
I), which breaks only one strand of DNA and topo II, 
which breaks both strands of the duplex (19). 
Alterations in DNA topo II have been identiﬁ ed in 
tumour cell lines selected for resistance to natural 
products, including etoposide and doxorubicin (18). 
Actinomycin D, bleomycin, daunorubicin, doxorubicin, 
elsamicin A, epirubicin, ethidium, m-AMSA, 
mitoxantrone are just some of the DNA intercalating 
drugs commonly used today as chemotherapeutics 
(22-28). 
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Indolocarbazoles represent a family of natural 
products with the potential to be used in cancer 
treatment (29). The natural antibiotic rebeccamycin 
(Figure 2) isolated from Saccharothrix aerocoloniegenes 
(30) is representative of the indolcarbazole group and 
is a DNA-binding agent and inhibitor of topo I (31-
33). 
toxicity of MLN944 was not correlated with the 
inhibition of topo I and topo II and that treatment 
induced non-reversible cell cycle arrest in both the G1 
and the G2-M phase. 
Figure 1  Schematics showing two distinct models of drug-DNA 
interaction. 
A) DNA major and minor groove binding – an 
isohelical drug molecule binds in the minor groove 
of DNA without inducing signiﬁ cant DNA structural 
changes; the complex is stabilised mainly with 
hydrophobic interactions; 
B) Intercalation – a planar aromatic chromophore 
is inserted between two adjacent base pairs in the 
DNA helix; the complex is stabilised by hydrophobic 
interactions and van der Waals forces.
Figure 2 Chemical structure of rebeccamycin
MLN944 (XR5944) (Figure 3) is a novel bis-
phenazine originating from a drug development 
programme aimed at developing new compounds as 
drugs for the treatment of solid tumours (34). This 
agent expressed strong cytotoxic activity in a variety 
of in vitro and in vivo tumour models. It was designed 
to target both topo-I and topo-II, but experiments 
conducted by Sappal et al. (35) showed that the 
Figure 3 Chemical structure of MLN944
Figure 4  Synthetic intercalating antineoplastic compounds 
[adapted from (36)]
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Two newly-synthesised drugs, named TAS-103 
and DACA (Figure 4), act as dual topo poisons. TAS-
103 is a quinoline derivate expressing remarkable 
activity against subcutaneously-implanted murine and 
human tumours in vivo, as well as various lung-
metastatic murine tumours (36). Recent studies on 
TAS-103 in conjunction with various approved 
antitumour drugs like cisplatin, if  applied 
simultaneously, expressed a synergistic effect, which 
may prove beneﬁ cial for the treatment of small-cell 
lung cancer. TAS-103 is therefore a promising 
anticancer compound and is currently undergoing 
clinical trials (37). The antitumour activity of DACA 
was extremely high in certain in vivo tumour models 
(38). For example, DACA was efficient against 
transplantable Lewis lung adenocarcinoma growing 
as lung tumour nodules in mice and was more 
successful than standard drugs in various xenografted 
cancers (37). DACA is currently in phase I/II clinical 
trial as an anticancer agent. One of the most interesting 
facts about DACA is its unusual mode of binding to 
DNA. It was revealed that the intercalation of the 
acridine ring was accompanied by a major groove 
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binding of the carboxamide side chain (39). Major 
groove binding is usually noted with proteins and 
peptides and infrequently seen in small molecules 
(37).
Prodiginines (Figure 5) are transformed primary 
bacteria products with immunosuppressive and 
anticancer attributes, characterised by a pyrrole 
dipyrromethane backbone. They act as a dual topo I/II 
inhibitor. Their antimalignant activity has been shown 
in several cancer-derived cell lines (breast, lung, 
stomach, liver, spleen, colon, blood, and chronic 
myeloid leukaemia) and in mice in vivo with a 
xenografted liver cancer (40). Furthermore, 
prodiginines show negligible activity in normal cells 
(31). Prodigiosin, a red pigment produced by numerous 
strains of the bacterium Serratia marcescens, is a 
prodiginine scanned against dozens of cancer cell lines 
demonstrating an average inhibitory concentration of 
2.1 μmol L-1 (41). Obatoclax (GX15-070) is a synthetic 
derivative of natural prodiginines and the leading 
candidate for clinical application. Currently, Obatoclax 
is in multiple phase I and phase II clinical trials for 
several types of cancer, used both as a single agent 
and in combined therapies (42, 43).
and cardiotoxicity and has produced high response 
rates in early breast cancer compared to doxorubicin 
(46). Mitoxantrone is an anthraquinone derivate 
structurally and functionally very similar to 
doxorubicin: it acts as an intercalator and topo II 
poison. It is used in the treatment of prostate cancer, 
acute myelogenous leukaemia (AML), breast cancer, 
and Non-Hodgkin’s lymphoma (47).
Figure 5  Prodigiosin and his derivative Obatoclax [adapted 
from (43)]
Anthracyclines act as topo II inhibitors. Doxorubicin 
and daunomycin are representatives of this group, as 
is aclacinomycin A, a dual topo inhibitor with the 
ability to kill cells in the exponential and plateau phase 
by a non-selective mechanism (37). Doxorubicin 
(Figure 6) is an anthracycline antibiotic with 
antineoplastic activity. It acts as a topo II poison and 
is used for treating breast and ovarian cancer, lung 
cancer, gastric (stomach) cancer, testicular cancer, 
bladder and thyroide cancer, Hodgkin’s and non-
Hodgkin’s lymphoma, soft tissue sarcoma, acute 
leukaemia, Wilm’s tumour and neuroblastoma (44). 
Since 2007, doxorubicin and bortezomib have been 
used in combined therapy for treating multiple 
myeloma (45). Epirubicin is also an anthracycline 
antibiotic. It expresses reduced myelosuppression 
Figure 6  Doxorubicin chemical structure and 3D intercalating 
model [adapted from (44)] 
DNA groove binders
Minor groove DNA binding compounds are a new 
family of antineoplastic drugs with representatives 
already in the process of clinical testing. The structure 
of these molecules is characterised by several 
connected aromatic rings that allow freedom of 
movement and torsion. Binders usually have a 
characteristic curved shape compatible with the DNA 
minor groove. The formed complex is stabilised with 
hydrophobic interactions (Figure 1A). Furthermore, 
DNA binders do not cause significant structural 
changes in the DNA molecule and no change to the 
DNA free energy structure (22). One of the most 
prominent characteristics of DNA minor groove 
binding compounds is their preferable binding to AT 
rich regions due to good hydrophobic interaction 
between the aromatic ring of the compound and second 
C atom of adenine. On cell level, DNA minor groove 
binders stop the cell cycle in its G2-M phase (48). 
MGBs are especially interesting because of their 
possible effect on gene expression, pronounced 
afﬁ nity, and selective binding. In the last decade, many 
synthetic and natural analogues like distamycin A, 
netropsin (49), CC-1065 (50), and Hoechst 33258 (51) 
were tested for their antineoplastic impact. Some 
possessed ﬂ uorescent attributes, with antibacterial, 
antifungal, and antiviral properties. They can be used 
in combination with other drugs for cytotoxic 
enhancement with an aim to reduce the applied drug 
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concentrations. For example, distamycin A in 
combination with duocarmycin A enhanced the 
cytotoxicity of duocarmycin A by 10 times in 
comparison with duocarmycin A alone (52).
Bisamidines are a group of compounds used as a 
base for the synthesis of new compounds with minor 
alterations in structure. The biological effects of 
bisamidines presumably originate from their inhibitory 
effects on transcription and replication (53). Hoechst 
33258 and 33342 are representatives of the bis-
benzimidazole group and probably one of the most 
studied DNA binding compounds (Figure 7).
binding properties. Besides settling into the minor 
groove of AT sequences (57), the drug can intercalate 
into GC-rich sequences (58). Analogue DNA 
sequence-dependent binding modes have been 
exhibited with DAPI and berenil and diphenylfuran 
derivatives. Hence, inactivation of topoisomerase I by 
Hoechst 33258 may, to a certain extent, rely on the 
intercalative binding mode rather than the DNA minor 
groove complex formation (37). Hoechst 33342 is 
more lipophilic than 33258 and is commonly applied 
for histochemical staining and flow cytometric 
analysis of DNA content in viable cells (59, 60). 
Curiously, Hoechst 33342 generated protein-DNA 
cross links and DNA strand breaks in cultured 
mammalian cells. G2-phase arrest and chromosome 
end reduplication were also pronounced effects of 
Hoechst 33342 treatment (61).
Terbenzimidazoles are a group of synthetic ligands 
that poison the human topo I enzyme and contribute 
to cancer cell death (49). One of its representatives is 
the 5-phenylterbenzimidazole derivative (5PTB), 
which poisons human topo I and is lethal to tumour 
cells that overexpress the multi-drug resistance protein 
(MDR) (49).
Pyrrolobenzodiazepines (PBDs) are a group of 
naturally occurring alkylating antitumour antibiotics. 
They are a class of sequence-selective DNA binding 
agents obtained from the thermophilic actinomycete 
Streptomyces refaineus (62), which includes DC-81, 
tomaymycin, and anthramycin (63). Anthramycin was 
isolated in 1963 and in spite of good antineoplastic 
activity against different types of tumours (Ehrlich 
solid carcinoma, sarcoma 180, epidermal carcinoma 
no.3 and leukaemia L1210 cells), the clinical 
application of anthramycin is limited because of its 
high cardio toxicity and possible appearance of acute 
necrosis at the site of drug application (62). SJG-136 
is a new member of the PBD group. This compound 
exhibited signiﬁ cant in vivo potential for leukaemia 
treatment. The first phase of clinical evaluation 
ﬁ nished in 2010 (64). The tripyrrole peptide distamycin 
A is a naturally occurring antibiotic agent obtained 
from the cultures of Streptomyces distallicus (62). It 
binds exclusively to the minor groove of DNA with 
high selectivity for the AT rich region (65). Distamycin 
A (Figure 8) is a potent inhibitor of Werner and Bloom 
syndrome helicases and a dual inhibitor of topo I and 
II. It inhibits RNA polymerase II transcription by 
blocking chain elongation as well as intensifying 
transcription at natural RNA polymerase II pause sites 
(66). One signiﬁ cant representative among distamycin 
Figure 7  Chemical structure of DNA binding dyes Hoechst 
33258 and 33342 used in ﬂ uorescent microscopy for 
DNA visualisation and detection
Hoechst 33258, known as pibenzimol, is a 
fluorescent reagent with a head-to-tail bis-
benzimidazole structure that initially showed activity 
against L1210 murine leukaemia (54). In human phase 
I clinical trials, it exhibited mild suppressive reaction 
in pancreatic cancer. However, phase II did not show 
any objective responses (54). Since Hoechst 33258 
possesses strong DNA binding power, many chemists 
have used it as a backbone for new compounds with 
different radicals and substituted groups or atoms. Not 
long ago, Liu et al. (55) have pinpointed Hoechst 
33342 and 33258 as delegates of a class of human 
topo I poisons that display cytotoxic behaviour in 
numerous cancer cell lines. These drugs bind to the 
minor groove of AT-tract duplex DNA. Nevertheless, 
this binding mode by itself does not seem adequate to 
reveal biological activity as a topo I poison, because 
other AT-speciﬁ c, minor groove-directed ligands, such 
as netropsin, 4´,6-diamidino-2-phenylindole (DAPI), 
berenil, and distamycin A were proven to be powerless 
or inert poisons of human topo I (56). Therefore, minor 
groove binding by itself, even though probably 
required, is not sufficient to poison topo I (56). 
However, Hoechst 33258 has uncommon DNA 
Mišković K, et al. ANTINEOPLASTIC DNA BINDING COMPOUNDS
Arh Hig Rada Toksikol 2013;64:593-602
598
A derivatives is tallimustine (TAM) (67). Until 
recently, TAM was the only clinically developed 
derivative (68). TAM passed phase I of clinical trials 
but was halted in phase II (69, 70), because it showed 
severe myelotoxicity (68). Netropsin (71)  acts in the 
same way as distamycin A, inhibiting Werner and 
Bloom syndrome helicases and dually inhibiting topo 
I/II. 
Other relatively frequently used drugs include the 
natural antibiotic duocarmycin SA, member of the 
CC-1065 family (72), which is a tremendously 
powerful cytostatic compound against different cancer 
cell lines and hence one of the most powerful 
anticancer agents known so far (73). Mithramycin 
(MTR) and chromomycine (Figure 9) have a similar 
mode of binding to GC-rich DNA sequences in the 
minor groove and belong to the aureolic acid group 
of anticancer drugs (66). 
CONCLUSION
The substances listed in this article are just some 
of the most frequent chemotherapeutic drugs and their 
forerunners. The mechanism of their action is speciﬁ c, 
but they have no particular selectivity toward 
malignant cells. The medicine of tomorrow will need 
to implement a personalised approach with tailored 
therapy for speciﬁ c patient transcription/genotype 
proﬁ les. Acquisition of effective substances through 
gene proﬁ ling in combination with proﬁ ciency gained 
through applied antimalignant therapy is the future 
recipe for successful treatment. 
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Sažetak
DNA-VEZUJUĆI ANTITUMORSKI SPOJEVI – INTERKALIRAJUĆI I MALI UTOR-VEZUJUĆI 
LIJEKOVI
Novo oružje u borbi protiv zloćudnih bolesti su spojevi koji se umeću u dvolančanu strukturu 
deoksiribonukleinskih kiselina (DNA) ili se vezuju na mali utor DNA. Navedene skupine kemoterapeutika 
primarno ciljaju molekulu DNA te utječu na stanični ciklus što vodi do smrti brzo dijelećih stanica. 
Uglavnom su derivati organskih spojeva prirodnog podrijetla, izoliranih iz mikroorganizama ili biljaka. 
DNA umetnuti spojevi uglavnom djeluju kao otrovi enzima topoizomeraza I i/ili II a spojevi koji se vezuju 
na mali utor DNA imaju kombinirani mehanizam djelovanja pri čemu je jedan od koraka i otrovanje 
topoizomeraza. U ovom preglednom članku dajemo pregled nekih od spojeva koji se umeću u molekulu 
DNA ili vezuju na mali utor DNA, a koji se primjenjuju u kemoterapiji, njihova podrijetla i kemijske 
strukture. 
KLJUČNE RIJEČI: derivati organskih spojeva, kemoterapija, mali utor DNA vezujući spojevi
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